ReviewTheranostics2018
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy.
Review in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed.
- Bibliometric analysis of programmed death ligand-1 positron emission tomography probe research: development, landscape, and technological evolution.Nuclear medicine communications · 2026Article
- Imaging lymphatic function and inflammation response through hypoxia via endogenous biomarker.Journal of biomedical optics · 2026Article
- Directed evolution-driven reprogramming of PD-L1 for compact and tunable checkpoint modulation.Journal of biological engineering · 2025Article
- Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade.European journal of nuclear medicine and molecular imaging · 2025Article
- The Role of Nuclear Medicine in Predicting Treatment Response to Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma: A Narrative Review.Journal of hepatocellular carcinoma · 2025Review
- Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG-3 and PD-L1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- [Immunotherapy advances · 2025Article
- Development of selective ssDNA micro-probe for PD1 detection as a novel strategy for cancer imaging.Scientific reports · 2024Article
- A PD-L1-Targeted Probe Cy5.5-A11 forACS omega · 2024Article
- Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma.Journal for immunotherapy of cancer · 2024Article
- Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.European journal of nuclear medicine and molecular imaging · 2024Article
- Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma.NPJ precision oncology · 2024Article
- Biomaterials' enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment.Frontiers in immunology · 2024Review
- Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics.Cancers · 2023Review
- Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy.Cancers · 2023Review
- An optimized radiosynthesis of [Journal of labelled compounds & radiopharmaceuticals · 2023Article
- Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Review
- Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display.ACS chemical biology · 2022Article
- Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology.International journal of molecular sciences · 2022Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular imaging of the immune checkpoint receptor PD-1 and its ligand PD-L1 is increasingly investigated as a strategy to guide and monitor PD-1:PD-L1-targeted immune checkpoint therapy. We provide an overview of the current state-of-the-art on PD-1- and PD-L1-specific imaging agents for quantitative, real-time assessment of PD-1:PD-L1 expression in the tumor environment and discuss their potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.